Could this Healthcare Stock really climb 160.22% by 2024?

Earnings Alert. If you cannot see this email properly, please click [here]( --------------------------------------------------------------- Sponsor Message [AI "wealth window" will close January 9, 2024?]( Next-generation AI technology will create the first $100 TRILLION industry. AI 2.0 will open a brief “wealth window”… That will slam shut January 9, 2024. [>>HERE is everything you need now<<]( --------------------------------------------------------------- November 1, 2023 (Earnings Report) From the desk of the Editor Dear Reader, We just identified several stocks that are expected to release earnings very soon. If you are interested in any of these companies, we encourage you to do your own research and due diligence before pursuing any investments. Keep in mind, the actual earnings date and time may change, so if you’re interested in any of these companies you will need to pay close attention to their announcements. --------------------------------------------------------------- Sponsor Message [Saudis joined BRICS to attack America?]( Our former ally Saudi Arabia just officially aligned with Russia, China, and Iran… [>>Saudi Arabia preparing “weapon of mass destruction”<<]( --------------------------------------------------------------- [Shopify]( Symbol: [SHOP]( Recent Price: $47.19 Average Analyst Price Target: $65.00 (42.25%) Market Cap: $56.47B Last Year's EPS: $0.01 Consensus EPS Forecast: $0.06 Expected Earnings Date: Nov 02 2023 Recent Analyst Action: Darren Aftahi, analyst at Roth MKM, reiterates coverage on [Shopify (SHOP)]( in the Technology sector with a Buy rating and a price target of $68 (1 day ago). [TipRanks.com]( also reports that [Shopify]( currently has 5 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $65.00 . The target pricing ranges from a high forecast of $75 down to a low forecast of $55. [Shopify (SHOP)](’s last closing price was $47.19 which would put the average price target at 42.25% upside. Here are 3rd party ratings for [SHOP](: - TipRanks.com: Moderate Buy - TradingView.com: Sell - Yahoo! Finance: Bearish Short-Term Outlook - Barchart.com: Strong sell - Zacks.com: Hold, Top 31% (76 out of 245) [Click for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- Sponsor Message [This New Tech Could Be Worth THREE TIMES the Entire New York Stock Exchange...]( believe this new tech will create more wealth than all the fortunes of the last 150 years combined. That’s why the world’s richest men and even the United States Senate approved throwing hundreds of BILLIONS of dollars into this new technology… [And right now, there’s a little-known stock at the center of all the action.]( In fact, this small-cap stock is still trading for less than it costs to buy a tank of gas. [Click here now for the whole story.]( --------------------------------------------------------------- [Zoetis]( Symbol: [ZTS]( Recent Price: $157 Average Analyst Price Target: $209.60 (40.61%) Market Cap: $72.27B Last Year's EPS: $1.31 Consensus EPS Forecast: $1.32 Expected Earnings Date: Nov 02 2023 Recent Analyst Action: Jonathan Block, analyst at Stifel Nicolaus, reiterates coverage on [Zoetis (ZTS)]( in the Healthcare sector with a Buy rating and a price target of $195 (1 day ago). [TipRanks.com]( also reports that [Zoetis]( currently has 5 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $209.60 . The target pricing ranges from a high forecast of $230 down to a low forecast of $195. [Zoetis (ZTS)](’s last closing price was $157 which would put the average price target at 40.61% upside. Here are 3rd party ratings for [ZTS](: - TipRanks.com: Strong Buy - TradingView.com: Sell - Yahoo! Finance: Bearish Short-Term Outlook - Barchart.com: sell - Zacks.com: Sell, Top 38% (92 out of 245) [Click for chart >>]( -------------------------------------------------------------------------- [Moderna]( Symbol: [MRNA]( Recent Price: $75.96 Average Analyst Price Target: $129.25 (113.27%) Market Cap: $28.19B Last Year's EPS: $0.19 Consensus EPS Forecast: -$3.84 Expected Earnings Date: Nov 02 2023 Recent Analyst Action: Tyler Van, analyst at TD Cowen, reiterates coverage on [Moderna (MRNA)]( in the Healthcare sector with a Hold rating and a price target of $100 (6 days ago). [TipRanks.com]( also reports that [Moderna]( currently has 4 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $129.25 . The target pricing ranges from a high forecast of $64 down to a low forecast of $100. [Moderna (MRNA)](’s last closing price was $75.96 which would put the average price target at 113.27% upside. Here are 3rd party ratings for [MRNA](: - TipRanks.com: Moderate Buy - TradingView.com: Sell - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: Strong sell - Zacks.com: Hold, Top 27% (66 out of 245) [Click for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- Sponsor Message [Get Access to Adam O'Dell's New AI Stock Rating System]( O’Dell, a pioneer in AI investing, is opening the doors to his patent pending stock rating system. The same system that predicted the crash of Silicon Valley Bank, Wayfair, Carvana and Beyond Meat months in advance — just released its newest findings. [Details here…]( --------------------------------------------------------------- [Insulet]( Symbol: [PODD]( Recent Price: $132.57 Average Analyst Price Target: $241.75 (86.41%) Market Cap: $9.13B Last Year's EPS: $0.23 Consensus EPS Forecast: $0.26 Expected Earnings Date: Nov 02 2023 Recent Analyst Action: William Plovanic, analyst at Canaccord Genuity, reiterates coverage on [Insulet (PODD)]( in the Healthcare sector with a Buy rating and a price target of $355 (1 week ago). [TipRanks.com]( also reports that [Insulet]( currently has 4 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $241.75 . The target pricing ranges from a high forecast of $355 down to a low forecast of $162. [Insulet (PODD)](’s last closing price was $132.57 which would put the average price target at 86.41% upside. Here are 3rd party ratings for [PODD](: - TipRanks.com: Moderate Buy - TradingView.com: Sell - Yahoo! Finance: Bearish Short-Term Outlook - Barchart.com: Strong sell - Zacks.com: Buy, Bottom 41% (145 out of 245) [Click for chart >>]( -------------------------------------------------------------------------- [Lantheus]( Symbol: [LNTH]( Recent Price: $64.60 Average Analyst Price Target: $118.80 (82.40%) Market Cap: $4.21B Last Year's EPS: $1.47 Consensus EPS Forecast: $1.31 Expected Earnings Date: Nov 02 2023 Recent Analyst Action: Roanna Ruiz, analyst at Leerink Partners, reiterates coverage on [Lantheus (LNTH)]( in the Healthcare sector with a Buy rating and a price target of $125 (1 week ago). [TipRanks.com]( also reports that [Lantheus]( currently has 5 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $118.80 . The target pricing ranges from a high forecast of $130 down to a low forecast of $100. [Lantheus (LNTH)](’s last closing price was $64.60 which would put the average price target at 82.40% upside. Here are 3rd party ratings for [LNTH](: - TipRanks.com: Strong Buy - TradingView.com: Sell - Yahoo! Finance: Bearish Short-Term Outlook - Barchart.com: Strong sell - Zacks.com: Sell, Bottom 41% (145 out of 245) [Click for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- Sponsor Message [EV Hesitation Resolved by the "Forever Battery"]( prices are hitting us all where it hurts — our wallets. But there’s still hesitation to buy electric vehicles. One tiny company’s breakthrough battery tech will knock out all those hesitations. A 15-minute charge could soon take you 1,000 miles. We call it the “Forever Battery” — getting in early could mean huge profits. [Click here to see how you could take advantage.]( --------------------------------------------------------------- [Denali Therapeutics]( Symbol: [DNLI]( Recent Price: $18.83 Average Analyst Price Target: $60.75 (160.22%) Market Cap: $2.53B Last Year's EPS: -$0.8 Consensus EPS Forecast: -$0.68 Expected Earnings Date: Nov 02 2023 Recent Analyst Action: Mayank Mamtani, analyst at B.Riley Financial, reiterates coverage on [Denali Therapeutics (DNLI)]( in the Healthcare sector with a Buy rating and a price target of $37.99 (1 day ago). [TipRanks.com]( also reports that [Denali Therapeutics]( currently has 4 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $60.75 . The target pricing ranges from a high forecast of $50 down to a low forecast of $105. [Denali Therapeutics (DNLI)](’s last closing price was $18.83 which would put the average price target at 160.22% upside. Here are 3rd party ratings for [DNLI](: - TipRanks.com: Strong Buy - TradingView.com: Sell - Yahoo! Finance: Bearish Short-Term Outlook - Barchart.com: Strong sell - Zacks.com: Buy, Top 27% (66 out of 245) [Click for chart >>]( -------------------------------------------------------------------------- [Prothena]( Symbol: [PRTA]( Recent Price: $36.46 Average Analyst Price Target: $76.75 (136.34%) Market Cap: $1.90B Last Year's EPS: -$0.89 Consensus EPS Forecast: -$0.92 Expected Earnings Date: Nov 02 2023 Recent Analyst Action: Tazeen Ahmad, analyst at Bank of America Securities, reiterates coverage on [Prothena (PRTA)]( in the Healthcare sector with a Buy rating and a price target of $70 (5 days ago). [TipRanks.com]( also reports that [Prothena]( currently has 4 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $76.75 . The target pricing ranges from a high forecast of $94 down to a low forecast of $60. [Prothena (PRTA)](’s last closing price was $36.46 which would put the average price target at 136.34% upside. Here are 3rd party ratings for [PRTA](: - TipRanks.com: Strong Buy - TradingView.com: Sell - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: Strong sell - Zacks.com: Buy, Top 27% (66 out of 245) [Click for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- Sponsor Message [Top market research firm: “A Gold Storm is Coming”]( of the richest men in the world are jumping in right now. One firm says: “We are in the early stages of a mania – the calm before the storm.” --------------------------------------------------------------- And there you have it--- Stocks expected to release earnings soon... Sincerely, The Editor, InsideTraderAlerts.com InsideTraderAlerts Disclaimer This newsletter contains advertisements which are neither an offer nor recommendation to buy or sell any security. Content marked as "Ad," "Special" or "Sponsor" may be a third party advertisements where the advertiser is paying per click, per lead or per sale and are not endorsed or warranted by our staff or company. Sandpiper Marketing Group, LLC is also being compensated by Summit Publishing Group and Investing Trends up to three dollars per click and may exceed twelve thousand, five hundred dollars per week for placement of specific advertisements contained in this newsletter. Sandpiper Marketing Group, LLC and its principles do not own any of the stocks mentioned in this email or in the article that this email links to. Please see the disclaimer on the advertiser's website for additional information, including their relationship with any mentioned security. Compensation for advertising constitutes a conflict of interest as to our ability to remain objective in our communication regarding any companies profiled. Because of this conflict, individuals are strongly encouraged to not use this newsletter as the basis for any investment decision. This newsletter may contain information regarding investment ideas and third-party ratings regarding specific securities. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. Sandpiper Marketing Group, LLC nor its principals are FINRA-registered broker-dealers or investment advisers. The content of this email should not be taken as advice, an endorsement, or a recommendation from Sandpiper Marketing Group, LLC to buy or sell any security. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment. The content in this newsletter or email is not provided to any individual with a view toward their individual circumstances. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. By opening this email or clicking any links contained, you are reconfirming your opt-in status. You can unsubscribe at any time by clicking the link below in the footer. [If you are not a human, click here.]( InsideTraderAlerts part of Sandpiper Marketing Group, LLC | 1519 Mecklenburg Hwy | Unit 4 | Mt. Mourne | NC | 28123 | United States | 877-411-9808 [Unsubscribe]( | [Report spam]( Sent with [ActiveTrail]( software